Back to search results

Brivaracetam for Epileptic Activity in Alzheimer's Disease

This study is looking at how a medication called brivaracetam might help people with mild cognitive impairment (MCI) or Alzheimer's disease who also show signs of epileptic activity in their brain. Researchers want to understand the brain activity in the hippocampus (a part of the brain important for memory) and see if brivaracetam can reduce this epileptic activity. They will also explore if brivaracetam can improve thinking and memory skills. You might be able to join if you are 45-70 years old, have MCI or Alzheimer's disease with specific brain biomarkers, and show epileptic activity. The study aims to enroll 25 participants. The main goal is to see how brivaracetam affects your thinking abilities after 3 months.

Study design
This is a pilot study, meaning it's a small-scale, initial investigation. It's an open-label study, so both you and the study team will know you are receiving brivaracetam. It plans to enroll 25 participants.
What's involved
You would undergo a hospital stay for brain recordings using scalp EEG and depth electrodes. During this time, you would receive brivaracetam intravenously. After this, you would take brivaracetam tablets for one year.
Compensation
Not stated in the trial record.
Follow-up
Your cognitive abilities will be measured at 3 months after starting brivaracetam.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05899764

Epileptic Hippocampus in Alzheimer's Disease

Not Yet Recruiting
PHASE1Ages 45–70InterventionalTreatment
University of California, Los Angeles
~25 participants
Updated 2026-01-27 on ClinicalTrials.gov
What's tested:Brivaracetam

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Brivaracetam on Cognition
Measured over 3 months
+1 more outcome measured

Conditions

Alzheimer Disease
Mild Cognitive Impairment

Explore related trials

Alzheimer's DiseaseMild cognitive disorder

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Keith A Vossel, MD, MSc · PRINCIPAL_INVESTIGATOR · Mary S. Easton Center at UCLA

Who to contact

Katy A Figueroa, Bachelor of Science
[email protected]
310-206-8993
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Meet research criteria for mild cognitive impairment (Albert et al. 2011) or Alzheimer's disease (McKhann et al. 2011) with high biomarker probability of Alzheimer's disease pathophysiology
Ages 45 to 70
Epileptic activity and/or pHFOs in temporal or fronto-temporal electrodes
Willing and able informant who has at least weekly contact with subject
Mini-Mental State Examination score of 18 or greater and/or Clinical Dementia Rating less than 2. These two examinations will be obtained from their participation in UCLA IRB#21-001603 or will be collected if subjects are referred by a clinician.

Exclusion

History of Korsakoff's syndrome
Alcohol or substance abuse preceding dementia \& still present within 5 years of onset
Untreated vitamin B12 or folate deficiency
History of head trauma with persistent deficits
Untreated syphilis
History of multiple sclerosis or another neuro-inflammatory disorder
History of vascular or multi-infarct dementia
Diagnosis of Huntington's disease
History of normal pressure hydrocephalus
History of CNS lesions deemed to be clinically significant
Unresolved or present subdural hematoma
History of intracerebral hemorrhage
Systematic liver disease
Renal insufficiency requiring dialysis
Encephalitis or meningitis
Severe white matter disease as defined by a score of 3 on the age-related white matter changes scale
Lacunar infarcts deemed to be clinically significant
Cortical stroke
Respiratory condition requiring oxygen
Untreated hypothyroidism 7. Any other medical condition which is determined by the investigators to potentially create an undue risk for an adverse event 8. Use of medications likely to affect CNS functions (e.g., benzodiazepines, narcotics). Patients are allowed to take cholinesterase inhibitors and memantine as long as the dosage is stable for 30 days prior to study entry.

What this trial measures

  • Brivaracetam on Cognition3 months

    To determine the efficacy of brivaracetam to improve cognitive function for the following task at 3 months while taking brivaracetam oral tablets: Stroop interference naming (number correct)

  • Brivaracetam on Cognition3 months

    To determine the efficacy of brivaracetam to improve cognitive function for the following task at 3 months while taking brivaracetam oral tablets: Virtual Route Learning Test (VRLT)